The ongoing Intensive Insulin Therapy vs. Plasmapheresis in the Management of Hypertriglyceridemia-Induced Acute Pancreatitis (Bi-TPAI) trial aims to evaluate whether intensive insulin therapy is non-inferior to plasmapheresis in patients with HTG-AP [185]. The gene discussed is INS; the disease is hypertriglyceridemia.